Plasma Brain Natriuretic Peptide Levels in Pregnancy - Full Text View

Purpose

To evaluate the maternal blood concentrations of brain natriuretic peptide (BNP) during the second and third trimesters of a normal pregnancy. We will attempt to define a normal range for pregnancy and any outliers that may serve as markers for abnormal cardiovascular physiology.

Condition

Cardiomyopathy
Pregnancy

MedlinePlus related topics:

Cardiomyopathy

ChemIDplus related topics:

Nesiritide

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective

Official Title:	Plasma Brain Natriuretic Peptide Levels in Pregnancy

Further study details as provided by Oklahoma State University Center for Health Sciences:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	50
Study Start Date:	August 2006
Study Completion Date:	June 2008

Groups/Cohorts

1

Healthy pregnant women, 18-40

Detailed Description:

The brain natriuretic peptide (BNP) is a useful marker for volume overload, increased filling pressures and stretching of the myocardium. The current literature contains limited and unreliable information regarding normal BNP values in pregnancy. After baseline echocardiogram to detect individuals with asymptomatic structural defects, the participants will submit to 3 blood draws during the second and third trimester and at delivery to determine normal pregnancy values.

Eligibility

Ages Eligible for Study:	18 Years to 40 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Healthy pregnant women, 18-40

Criteria

Inclusion Criteria:

women age 18 to 40
second trimester of pregnancy

Exclusion Criteria:

known cardiac or valvular disease,
atrial fibrillation or other arrhythmia,
pulmonary hypertension,
chronic hypertension,
hypertensive disorders of pregnancy,
morbid obesity (BMI > 40 kg/meter squared)
history of sleep apnea
multiple gestation
known renal dysfunction
medications known to affect cardiac function
current or past abnormal echocardiogram

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00324402

Locations


United States, Oklahoma
	Oklahoma State University Center for Health Sciences
	Tulsa, Oklahoma, United States, 74127

Sponsors and Collaborators

Oklahoma State University Center for Health Sciences

Investigators


Study Chair:	Kimberly A Sorensen, DO	Oklahoma State University Center for Health Sciences

Principal Investigator:	John M Beal, DO	Oklahoma State University Center for Health Sciences

More Information

Responsible Party:	Oklahoma State University Center for Health Sciences ( Dr. J. Martin Beal, assistant professor of Ob/Gyn )
Study ID Numbers:	2005008
First Received:	May 9, 2006
Last Updated:	July 8, 2008
ClinicalTrials.gov Identifier:	NCT00324402
Health Authority:	United States: Institutional Review Board

Keywords provided by Oklahoma State University Center for Health Sciences:

brain natriuretic peptide

pregnancy

biomarker

Study placed in the following topic categories:

Natriuretic Peptide, Brain

Heart Diseases

Cardiomyopathies

Additional relevant MeSH terms:

Natriuretic Agents

Therapeutic Uses

Physiological Effects of Drugs

Cardiovascular Diseases

Cardiovascular Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 03, 2008

Sponsored by:	Oklahoma State University Center for Health Sciences
Information provided by:	Oklahoma State University Center for Health Sciences
ClinicalTrials.gov Identifier:	NCT00324402